ArticleEmerging infectious diseases2012
VIM-2-producing multidrug-resistant Pseudomonas aeruginosa ST175 clone, Spain.
Article in Emerging infectious diseases, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- Prevalence of colistin resistance in clinical isolates ofFrontiers in microbiology · 2024Pooled it
- High-risk lineages shape the resistome and virulome of multidrug-resistantFrontiers in cellular and infection microbiology · 2026Article
- Pseudomonas aeruginosa: ecology, evolution, pathogenesis and antimicrobial susceptibility.Nature reviews. Microbiology · 2025Review
- Genetic diversity, biochemical properties, epidemiology, and detection methods of IMP- and VIM-type carbapenemases.Clinical microbiology reviews · 2025Review
- Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2025Review
- High-riskHeliyon · 2025Article
- The First Swedish Outbreak with VIM-2-ProducingMicroorganisms · 2023Article
- Association of Biofilm Inducer withArchives of Razi Institute · 2022Article
- A Study in a Regional Hospital of a Mid-Sized Spanish City Indicates a Major Increase in Infection/Colonization by Carbapenem-Resistant Bacteria, Coinciding with the COVID-19 Pandemic.Antibiotics (Basel, Switzerland) · 2021Article
- Retrospective Data Insight into the Global Distribution of Carbapenemase-ProducingAntibiotics (Basel, Switzerland) · 2021Article
- Diversity and Distribution of Resistance Markers inMicroorganisms · 2021Review
- Article
- Intra- and Extra-Hospital Dissemination of IMP-22-ProducingFrontiers in microbiology · 2021Article
- Mobile Carbapenemase Genes inFrontiers in microbiology · 2021Review
- Virulence and resistance determinants inJournal of advanced veterinary and animal research · 2020Article
- Prevalence of metallo-β-lactamase-producingNew microbes and new infections · 2020Article
- Pathogenic characteristics of Pseudomonas aeruginosa bacteraemia isolates in a high-endemicity setting for ST175 and ST235 high-risk clones.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020Article
- Predictors of Mortality in Bloodstream Infections Caused by Pseudomonas aeruginosa and Impact of Antimicrobial Resistance and Bacterial Virulence.Antimicrobial agents and chemotherapy · 2020Article
- High Expression of Metallo-β-Lactamase Contributed to the Resistance to Carbapenem in Clinical Isolates ofInfection and drug resistance · 2020Article
- Epidemiology and Mechanisms of Resistance of Extensively Drug Resistant Gram-Negative Bacteria.Antibiotics (Basel, Switzerland) · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A total of 183 patients were colonized or infected with multidrug-resistant Pseudomonas aeruginosa isolates at a hospital in Spain during 2007-2010; prevalence increased over this period from 2.8% to 15.3%. To characterize these isolates, we performed molecular epidemiologic and drug resistance analysis. Genotyping showed that 104 (56.8%) isolates belonged to a single major clone (clone B), which was identified by multilocus sequence typing as sequence type (ST) 175. This clone was initially isolated from 5 patients in 2008, and then isolated from 23 patients in 2009 and 76 patients in 2010. PCR analysis of clone B isolates identified the bla(VIM-2) gene in all but 1 isolate, which harbored bla(IMP-22). ST175 isolates were susceptible to only amikacin (75%) and colistin (100%). Emergence of the ST175 clone represents a major health problem because it compromises therapy for treatment of P. aeruginosa nosocomial infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.